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Available online 12 March 2016Objective. Limited research has examined the effects of antihypertensive medication use and physical func-
tion. These studies providedmixed ﬁndings while employing a convenience sample and limiting their examina-
tion to few indices of physical function and few classes of antihypertensivemedications. The purpose of this study
was to examine whether several antihypertensive medication classes were associated with several measures of
physical function in a national sample of U.S. middle-to-older age adults.
Methods. Data from the 1999–2002 and 2011–2012 NHANES were used. Antihypertensive medication use
was assessed from an interviewer, and included angiotensin converting enzyme (ACE) inhibitors, peripherally-
acting antiadrenergic agents and centrally-acting antiadrenergic agents. Physical function-related parameters in-
cluded objectively-measured lower extremity isokinetic knee extensor strength (IKES), objectively-measured
grip strength, laboratory-assessedwalking performance (8 and 20 ft walk tests) and self-reported physical activ-
ity engagement.
Results. Those on ACE inhibitors had a 37% reduced odds (OR=0.63, 95% CI: 0.48–0.83, P= .002) of engaging
in moderate-to-vigorous physical activity, had reduced knee extensor strength (β=−15.4, 95% CI:−27.2 to
−3.4, P = .01) and took longer to complete the 20 ft (β= .42, 95% CI: 0.02–0.81, P = .04) and 8 ft walking
tests (β= .22, 95% CI: 0.05–0.39, P = .01). Those on peripherally-acting antiadrenergic agents had reduced
grip strength (β=−4.8, 95% CI:−9.1 to−0.5, P= .02).
Conclusions. Antihypertensive medication use, particularly ACE inhibitors, is associated with various mea-
sures of reduced physical function. Clinicians are encouraged to monitor the long-term mobility function of
their patients on antihypertensive medications.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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It is reported that 1 out of 3 American adults (77.9million) have high
blood pressure (Go et al., 2013). A number of medications are pre-
scribed to reduce cardiovascular complications associated with hyper-
tension. Of these, the angiotensin converting enzyme (ACE) inhibitors
may have the potential to concurrently improve both cardiovascular
health and muscle function. ACE inhibitors prevent the conversion of
Angiotensin I to Angiotensin II in the renin-angiotensin system. Angio-
tensin II, in animal models, can promotemuscle loss by an inhibitory ef-
fect on the insulin like growth factor-1 (IGF-1) system and by
stimulating catabolism via the atrogenes (Yoshida et al., 2010). In
humans, those with the II genotype of the ACE gene have low serum
ACE levels and display better endurance performance as well as greaterlogy Laboratory, Department of
e University of Mississippi, 229
. This is an open access article underendurance following training (Woods et al., 2000). ACE inhibitors have
also been found to be associated with increased muscle size and
strength in those with hypertension (Onder et al., 2002; Di Bari et al.,
2004), which is an important ﬁnding as muscular strength is associated
with various health outcomes (Loprinzi et al., 2015) and reduced lower
extremity muscular strength is linked with impaired mobility (Batista
et al., 2012), which in turn is associated with quality of life and prema-
ture mortality (Rizzoli et al., 2013; Masel et al., 2010).
Not all studies, however, have demonstrated a favorable effect of ACE
inhibitors on physical function. This discrepancy across studies may be
explained by an inverted J-shape relationship between physical function
and the activity of the renin-angiotensin system or may be related to the
performance taskmeasured. To illustrate, previous studies noting a favor-
able effect of ACE inhibitors on physical performance have largely mea-
sured exercise capacity by using a walk test (Hutcheon et al., 2002;
Ahimastos et al., 2006; Sumukadas et al., 2007); however, not all studies
support this ﬁnding. Sumukadas et al. failed to ﬁnd an enhancement of
exercise capacity (walk test) or grip strength with ACE inhibitors com-
pared to those receiving a placebo (Sumukadas et al., 2014). Lastly, one
study reported a negative association between ACE inhibitor usethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Gray et al., 2012).
These mixed ﬁndings warrant the need for additional work on this
topic. Speciﬁcally, there is a need to examine the effects of ACE inhibi-
tors, as well as other anti-hypertensive medications, on multiple con-
current indices of physical function (e.g., muscular strength, free-
living physical activity, laboratory-based ambulatory performance). To
our knowledge, no such systematic study exists. Therefore, the purpose
of this study was to comprehensively examine the effect of antihyper-
tensive medication (ACE inhibitors, centrally- and peripherally-acting
antiadrenergic agents) use on various indices of physical function, in-
cluding objectively-measured lower extremity muscular strength,
free-living physical activity, laboratory-based walking velocity perfor-
mance, and grip strength.2. Methods
2.1. Design and participants
Data were extracted from several cycles of the National Health and
Nutrition Examination Survey (NHANES). All outcome measures were
not consistently evaluated across the same NHANES cycles. Cycles
1999–2002 included assessments of physical activity and lower extrem-
ity muscular strength; cycle 2001–2002 included assessments of walk-
ing performance; and cycle 2011–2012 included an assessment of grip
strength. See the Fig. 1 for the analyzed sample sizes for each analytic
model. For all analyses, the sample included those 50 yrs of age and
older as few participants under this age were on antihypertensiveFig. 1. Participant (all participants ≥50 yrs) ﬂow chart and results examining the association be
performance and grip strength. In a logistic regression, those on ACE inhibitors had a 37% red
linear regression, those on ACE inhibitors had reduced knee extensor strength (β=−15.4, P
(β= .48, P= .04) and 8 ft walking tests (β= .22, P= .01). In a linear regression, those on per
all analyses across all cycles, covariates included: age, gender, race-ethnicity, BMI, diabetes, m
ACE = Angiotensin-converting-enzyme inhibitor; PAA= Peripherally-acting antiadrenergic agemedication and only those 50+ yrs were eligible for the lower extrem-
ity muscular strength test, walking tests, and grip strength test. Proce-
dures were approved by the National Center for Health Statistics
review board. Consent was obtained from all participants.
2.2. Antihypertensive medication
During a household interview, participants were asked if they were
taking any prescription medication, and if so, how long (# of days) they
were taking the medication. Participants self-reporting medication use
were asked to show the interviewer the medication container(s), in
which the interviewer then entered the product's complete name from
the container into a computer. If no container was available, the
interviewer asked the participant to verbally report the name of
the medication. Due to the availability of data, antihypertensive
medication use was deﬁned as taking ACE inhibitors (e.g., captopril,
enalapril, fosinopril, quinapril, ramipril, benazepril, lisinopril, moexipril,
trandolapril, perindopril), peripherally acting antiadrenergic agents
(e.g., guanethidine, prazosin, reserpine, terazosin, guanadrel, doxazosin,
tamsulosin, alfuzosin, silodosin) and/or centrally acting antiadrenergic
agents (e.g., clonidine, guanabenz, methyldopa, guanfacine).
2.3. Peak lower extremity muscle strength
In the 1999–2002 NHANES cycles (Fig. 1), a Kin ComMP dynamom-
eter (Chattanooga Group, Inc.)was used to assess isokinetic knee exten-
sor strength (IKES) at peak force in newtons (at a speed of 60 degrees/s).
A total of 6 measurements of muscle strength of the right quadricepstween antihypertensive medication and physical activity, knee extensor strength, walking
uced odds (OR = .63, P = .002) of engaging in physical activity in the last 30 days. In a
= .01). In a linear regression, those on ACE inhibitors took longer to complete the 20 ft
ipherally-acting antiadrenergic agents had reduced grip strength (β=−4.8, P= .02). For
ean arterial pressure, coronary artery disease, smoking and duration of medication use.
nts; CAA = Centrally-acting antiadrenergic agents.
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measurements. If a participant completed 4–6 measures, the highest
peak forcewas selected from trials 4 to 6; if, however, a participant com-
pleted fewer than 4 measures, the highest peak force from the warm-up
trials was selected.
2.4. Physical activity
In the 1999–2002 NHANES cycle (Fig. 1), and based on the Global
Physical Activity Questionnaire, which has demonstrated evidence of
reliability and validity, (Bull et al., 2009) participantswere asked the fol-
lowing questions regarding engagement in moderate and vigorous-
intensity physical activity:
“Over the past 30 days, did you domoderate activities for at least 10mi-
nutes that cause only light sweating or a slight to moderate increase in
breathing or heart rate?”
“Over the past 30 days, did you do vigorous activities for at least 10 mi-
nutes that caused heavy sweating, or large increases in breathing or heart
rate?”
We created amoderate-to-vigorous physical activity variable noting
whether they engaged inmoderate or vigorous-intensity physical activ-
ity in the past 30 days (yes/no).
2.5. Walking tests
In the 2001–2002 NHANES cycle (Fig. 1), while in a corridor at the
mobile examination center, participants were instructed to “walk at
their usual” pace over a 20 ft distance. Timing was performed using a
hand-held stopwatch. The time started when the participant's ﬁrst
foot touched the ﬂoor across the start line. Two outcome measures
were recorded: time to walk 8 ft and 20 ft. The stop time for the 8 ft
walk was when the participant's foot touched the ﬂoor across the 8 ft
line, and stop time for the 20 ft walk was when the participant's foot
touched the ﬂoor across the ﬁnish line (20 ft mark).
2.6. Grip strength
In the 2011–2012 NHANES cycle (Fig. 1), grip strength (kg) was
assessed using the Takei digital grip strength dynamometer (Model
T.K.K. 5401). With the arm parallel to the side of the body, testing was
performed in a standing position unless the participant was physically
limited. Participants were instructed to squeeze the dynamometer as
hard as possible while exhaling. Tests were completed on both hands,
with each hand tested 3 times, alternating hands between trials with a
60 s recovery period between trials. For our purposes, we used the com-
bined grip strength by summing the largest reading from each hand.
2.7. Covariates
Unless noted otherwise, the following covariates, which were consis-
tent across the cycles, were included in each multivariable regression
model: age (yrs; continuous); gender (male/female); race-ethnicity (Mex-
ican American, other Hispanic, non-Hispanic white, non-Hispanic black,
other); measured body mass index (kg/m2; continuous); measured
mean arterial pressure (mmHg; continuous), calculated as ([diastolic
blood pressure × 2 + systolic blood pressure] / 3); physician-diagnosis
of diabetes and coronary artery disease; self-report smoking status (current
smoker, former smoker, never smoked); and duration of antihyperten-
sive medication use.
2.8. Statistical analysis
Statistical signiﬁcance was set at p b 0.05. Statistical analyses were
performed using procedures from survey data using Stata (v.12) to ac-
count for oversampling, non-response, non-coverage, and to provide
nationally representative estimates. Multivariable linear regressionwas used to examine the association of antihypertensive medication
use (independent variable) and IKES, walking performance, and grip
strength. Multivariable logistic regression was used to examine the as-
sociation of antihypertensive medication use and physical activity.
Models were computed separately for each of the primary outcomes.
Models were also computed separately for the three evaluated antihy-
pertensive medications.
3. Results
Characteristics of the study variables across the evaluated cycles are
shown in Table 1. Estimates for the covariates were similar across the
cycles. Differences in covariate estimates (e.g., age, gender proportion)
among those using and not reporting use of anti-hypertensive medica-
tions is shown in Table 2. Generally, and across cycles 1999–2002 and
2011–2012, those reporting use of anti-hypertensive medications (vs.
not) were older, more likely to be male, had a higher body mass
index, and more likely to have diabetes and coronary artery disease
history.
Results of the primary analyses are shown in Fig. 1. In amultivariable
logistic regression, those on ACE inhibitors, compared to those not on
ACE inhibitors, had a modest 37% reduced odds (OR = 0.63, 95% CI:
0.48–0.83, P= .002) of engaging in moderate-to-vigorous physical ac-
tivity in the last 30 days. In a multivariable linear regression, those on
ACE inhibitors, compared to those not onACE inhibitors, had a relatively
minimal, yet statistically reduced knee extensor strength (β=−15.3,
95% CI:−27.2 to−3.4, P = .01). In a multivariable linear regression,
those on ACE inhibitors, compared to those not on ACE inhibitors, took
longer to complete the 20 ft (β= .42, 95% CI: 0.02–0.81, P= .04) and
8 ft walking tests (β= .22, 95% CI: 0.05–0.39, P= .01). Lastly, in a mul-
tivariable linear regression, those on peripherally-acting antiadrenergic
agents, compared to those not on these agents, had a modest reduced
grip strength (β=−4.8, 95% CI:−9.1 to−0.5, P= .02).
It was not possible to include all outcome variables in the samemodel
given the inconsistent evaluation of the outcomes across the NHANES cy-
cles. However, physical activity and knee extensor strengthwere evaluat-
ed in the same cycles. When physical activity was included as a covariate
in the knee extensor strengthmodel, the association between ACE inhib-
itors and knee extensor strength remained signiﬁcant (β=−13.0, 95%
CI:−25.4 to−0.58, P = .04). Similarly, when knee extensor strength
was included as a covariate in the physical activitymodel, the association
between ACE inhibitors and physical activity remained signiﬁcant (OR=
0.65; 95% CI: 0.44–0.95; P= 0.02). Notably, there was no evidence of a
multiplicative interaction effect of ACE inhibitors and physical activity
on knee extensor strength (βinteraction = −10.8; 95% CI: −29.8–8.2;
P=0.25). Similarly, therewas no evidence of amultiplicative interaction
effect of ACE inhibitors and knee extensor strength on physical activity
(βinteraction = 0.001; 95% CI:−0.001–0.003; P= 0.63). Also, additional
analyses were computed that controlled for other potential confounders.
When a physical function proxy measure (“Does a physical, mental or
emotional problem now keep you from working at a job or business?”
Yes/No response) was included as a covariate, ACE-inhibitors remained
signiﬁcantly associated with reduced physical activity engagement
(OR = 0.63; 95% CI: 0.48–0.82; P = 0.01). Similarly, ACE-inhibitors
remained signiﬁcantly associated with reduced knee extensor strength
after including this covariate in the model (β=−15.0, 95% CI:−26.3
to−3.6, P=.01). Inclusion of other covariates (e.g., congestive heart fail-
ure, arthritis, cholesterol medication use) in all models did not alter the
ﬁndings (data not shown).
As stated above, those on peripherally-acting antiadrenergic agents,
compared to those not on these agents, had a modest reduced grip
strength (β=−4.8, 95% CI:−9.1 to−0.5, P= .02). When physical ac-
tivity was included as a covariate in this model, the conclusion was un-
changed (β=−4.9, 95% CI:−8.9 to−0.9, P= .02).
Lastly, several sensitivity analyses were computed. Given that it is
plausible to suggest that the observed association between
Table 1
Weighted characteristics (means/proportions [95% CI]) of the study variables across the NHANES cycles for which the parameter outcome was assessed.
NHANES
1999–2002
NHANES
2001–2002
NHANES 2011–2012
Variable Physical activity analysis Knee extensor analysis 20 ft walking analysis 8 ft walking analysis Grip strength analysis
N 3993 2920 1863 1863 1476
% engaging in MVPA 54.5 (50.5–58.4) – – – –
Peak muscle strength, mean newtons – 365.0 (359.4–370.5) – – –
20 ft walk, sec – – 6.23 (6.10–6.36) – –
8 ft walk, sec – – – 2.52 (2.47–2.57) –
Grip strength, kg – – – – 67.7 (66.3–69.0)
Age, yrs 63.4 (63.0–63.8) 62.5 (62.1–63.0) 62.7 (62.0–63.3) 62.7 (62.0–63.3) 62.5 (61.9–63.1)
Gender, %
Female 53.8 (52.6–55.0) 52.6 (51.2–54.1) 53.3 (51.5–55.1) 53.3 (51.5–55.1) 49.6 (46.0–53.1)
Race-ethnicity, %
Non-Hispanic white 79.4 (75.3–83.5) 80.8 (77.0–84.6) 82.0 (76.4–87.5) 82.0 (76.4–87.5) 74.6 (67.4–81.8)
BMI, kg/m2 28.5 (28.1–28.8) 28.2 (27.8–28.5) 28.4 (28.0–28.9) 28.4 (28.0–28.9) 28.9 (27.9–29.8)
% diabetes 12.3 (11.1–13.5) 10.2 (9.0–11.3) 12.2 (10.6–13.8) 12.2 (10.6–13.8) 15.0 (12.6–17.3)
MAP, mmHg 92.9 (92.1–93.7) 93.0 (92.2–93.9) 92.6 (91.4–93.8) 92.6 (91.4–93.8) 90.8 (89.5–92.1)
% CAD 8.0 (6.8–9.1) 6.7 (5.4–7.8) 8.3 (6.3–10.2) 8.3 (6.3–10.2) 5.1 (3.4–6.9)
Smoking status, %
Current smoker 16.2 (14.2–18.1) 16.0 (14.0–18.0) 17.2 (14.5–19.8) 17.2 (14.5–19.8) 16.1 (13.0–19.0)
Former smoker 37.9 (35.2–40.5) 38.6 (36.0–41.2) 37.3 (33.3–41.2) 37.3 (33.3–41.2) 31.7 (27.7–35.6)
Never smoker 45.8 (43.3–48.2) 45.3 (42.7–47.8) 45.4 (41.2–49.6) 45.4 (41.2–49.6) 52.3 (48.9–55.6)
Duration on medication, days 292.3 (256.3–328.4) 271.0 (228.2–313.8) 303.9 (262.4–345.5) 303.9 (262.4–345.5) 479.8 (363.1–596.6)
% of ACE inhibitors 11.9 (10.4–13.4) 10.6 (9.0–12.2) 12.2 (10.4–14.1) 12.2 (10.4–14.1) 15.4 (11.8–19.1)
% on PAA 3.4 (2.7–4.2) 3.6 (2.8–4.3) 3.3 (2.1–4.4) 3.3 (2.1–4.4) 3.3 (2.0–4.6)
% on CAA 1.2 (0.7–1.6) 1.0 (0.4–1.6) 0.9 (0.2–1.5) 0.9 (0.2–1.5) 1.1 (0.4–1.9)
MVPA, moderate-to-vigorous physical activity.
BMI, body mass index.
MAP, mean arterial pressure.
CAD, coronary artery disease.
ACE, angiotensin converting enzyme.
PAA, peripherally-acting antiadrenergic agents.
CAA, centrally-acting antiadrenergic agents.
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a result of an underlying pathology (e.g., hypertension) for which the
antihypertensive medication is used to treat, we computed separate
models among those with and without measured hypertension
(≥140/90 mmHg). As an example, and after complete adjustment, ACE
inhibitor use was associated with reduced engagement in physical ac-
tivity among those with hypertension (unregulated blood pressure)
(OR = 0.58; 95% CI: 0.35–0.93; P = 0.02) as well as those withoutTable 2
Weighted demographic characteristics (means/proportions [95% CI]) across anti-hypertensive
NHANES
1999–2002
Variable No anti-hypertensives On anti-hypert
N 2404 516
Age, yrs 62.0 (61.6–62.5) 65.4 (64.4–66.
Gender, %
Female 54.8 40.8
Race-ethnicity, %
Non-Hispanic white 81.0 79.9
BMI, kg/m2 27.8 (27.5–28.2) 29.8 (29.1–30.
% diabetes 8.2 21.4
MAP, mmHg 93.2 (92.3–94.1) 92.3 (90.7–93.
% CAD 5.2 14.4
Smoking status, %
Current smoker 17.2 9.2
Former smoker 36.7 49.5
Never smoker 46.0 41.3
MVPA, moderate-to-vigorous physical activity.
BMI, body mass index.
MAP, mean arterial pressure.
CAD, coronary artery disease.hypertension (regulated blood pressure) (OR = 0.68; 95% CI: 0.47–
0.98; P = 0.04). These results suggest that hypertensive status is not
driving the antihypertensive medication-physical function relationship.
This ﬁnding is not unexpected as our primary analyses observed an an-
tihypertensive medication-physical function relationship independent
of variousmorbidities, such as blood pressure, diabetes status, coronary
artery disease, arthritis, and congestive heart failure. It is also plausible
to suggest that advanced age may be driving the antihypertensivemedication use status.
NHANES
2011–2012
ensives No anti-hypertensives On anti-hypertensives
1134 342
4) 61.6 (61.0–62.2) 66.2 (64.8–67.6)
53.1 35.8
75.4 71.4
5) 28.4 (27.8–29.1) 30.6 (28.2–33.1)
11.3 29.8
9) 90.9 (89.4–92.5) 90.1 (88.0–92.1)
3.6 11.2
16.4 14.8
30.3 37.0
53.3 48.2
268 P.D. Loprinzi, J.P. Loenneke / Preventive Medicine Reports 3 (2016) 264–269medication-physical function relationship given that age is associated
with both antihypertensive medication use and physical function. Our
primary analyses observed an association between antihypertensive
medication and physical function independent of age (agewas included
as a covariate), with our sensitivity analyses showing that, for example,
ACE inhibitor use was associated with reduced physical activity among
those under 65 yrs (ORadjusted = 0.58; 95% CI: 0.38–0.88; P = 0.01)
as well as those 65 and older (ORadjusted = 0.69; 95% CI: 0.51–0.93;
P = 0.02). We also included the use of other medications
(e.g., cholesterol medication, statins) as covariates, but results were un-
changed with their inclusion. Notably, results were similar when con-
sidering the other physical function parameters. For example, there
was no interaction effect of ACE inhibitors and blood pressure on knee
extensor strength (βinteraction = 7.7; 95% CI: -14.1-29.6; P = 0.47);
similarly, therewas no interaction effect for ACE inhibitors and coronary
artery disease (βinteraction = 1.1; 95% CI: -39.3-41.5; P = 0.95), ACE
inhibitors and diabetes (βinteraction =−0.23; 95% CI: -34.1-33.6; P =
0.98), orACE inhibitors andcholesterolmedication (βinteraction=−0.87;
0.87; 95% CI: -26.7-24.9; P= 0.94) on knee extensor strength.
4. Discussion
The major ﬁnding of this study was that antihypertensive medica-
tion use, particularly ACE inhibitors, was associated with reduced en-
gagement in physical activity, reduced lower extremity knee extensor
strength, and reduced walking speed, with peripherally-acting
antiadrenergic agents associated with reduced grip strength.
The observedﬁnding that antihypertensivemedication use is consis-
tently associated with reduced physical function is in partial contrast to
the limited collective work on this topic. Prior to this study, the ﬁndings
regarding the relationship betweenACE inhibitors and physical function
have been mixed. Separate studies have found different effects for the
same test (e.g., walking-based test), i.e., some report a positive associa-
tion (Hutcheon et al., 2002; Ahimastos et al., 2006; Sumukadas et al.,
2007) between ACE inhibitors and walking performance while others
report no association betweenwalking performance and ACE inhibitors
(Sumukadas et al., 2014). Relatedly, Gray et al.(Gray et al., 2012) report-
ed a negative association between ACE inhibitor use and measures of
physical performance (e.g. chair stand, grip strength), with Sumukadas
et al.(Sumukadas et al., 2014) failing toﬁnd an enhancement of exercise
capacity (walk test) or grip strength with ACE inhibitors compared to
those receiving a placebo. Thus, prior to the present study, the mixed
ﬁndings in the literature suggested a task-speciﬁc association between
ACE inhibitors and exercise-related capacity. Alternatively, the prior in-
consistent ﬁndings may reﬂect pharmacogenomic differences among
individuals as well as study differences regarding the populations
employed.
To our knowledge, the present study is the ﬁrst to comprehensively
examine the concurrent association of antihypertensive medication use
and physical function. The consistent ﬁndings observed in the present
study are not in support of, for example, a task-speciﬁc association be-
tween antihypertensive medication use and physical function. We ob-
served a consistent association of antihypertensive medication use
(particularly ACE inhibitors) on various tests of physical function. Al-
though speculative, the consistent detrimental effect observed with
ACE inhibitors suggests that modulating the activity of the renin-
angiotensin system may be important, particularly the conversion step
of Angiotensin I to Angiotensin II. Regarding aerobic-based activities
(e.g., moderate-to-vigorous physical activity), long-term ACE inhibitor
use may precipitate fatigue and respiratory-related complications
(e.g., dyspnea), (Fowler et al., 2012; Overlack, 1996) which ultimately
may restrict engagement in physical activity participation. Further,
long-term or excessive use of ACE inhibitors may, perhaps, induce
over-vasodilation leading to reduce cardiac output, and subsequently,
reduced physical function (Williams et al., 2001). However, in the
present study, the use of ACE inhibitors was associated with reducedphysical activity engagement independent of medication duration use.
Wewere, however, not able to control for medication dose as this infor-
mation was not available from the participants.
It is difﬁcult to explain the observation of ACE inhibitor use and re-
duced muscular capacity. Plausibly, reduced muscular capacity may be
a result of ACE inhibitor-induced physical inactivity. However, the asso-
ciation between ACE inhibitor use and muscular capacity was signiﬁ-
cantly independent of physical activity, suggesting that another
mechanismmay be present. Alternatively, the relatively crudemeasure
of physical activity may have minimized any potential attenuation ef-
fect. Although it is plausible to suggest a detrimental effect of ACE inhib-
itor use on physical function, it is equally plausible to suggest that this
association may merely be a result of the underlying pathology for
which themedicationwasprescribed. For example, individualswith hy-
pertensionmayhave reducedmuscular strength and aerobic capacity as
a result of hypertension-induced sarcopenia (Han et al., 2014) or due to
other exercise-related pathologies (e.g., diabetes, obesity) that are asso-
ciated with hypertension. Notably, however, the associations between
ACE inhibitor use and each of the evaluated indices of physical function
remained signiﬁcant after controlling for bodymass index, diabetes and
blood pressure. Further, as noted in our sensitivity analyses, morbidity
status did notmoderate the association between antihypertensivemed-
ication use and physical function.
In conclusion, we observed a consistent association of antihyperten-
sive medication use, particularly ACE inhibitors, on reduced physical ac-
tivity engagement, lower knee extensor strength, reduce grip strength
and worse walking performance. Limitations of this study include the
cross-sectional design, rendering temporality not possible. Another limi-
tation is that participants may have been taking other anti-hypertensive
medications not evaluated herein or on other pharmaceutical agents
which could have inﬂuenced our observations.Major strengths of this in-
vestigation include the study's novelty, employing a national sample of
U.S. adults, and utilizing several objective measures of exercise perfor-
mance. Additional longitudinalmediational analyses are needed to deter-
mine if reduced mobility (as a possible result of reduced muscular
strength and physical activity engagement)mediates the relationship be-
tween antihypertensive medication use and morbidity/mortality. In the
meantime, clinicians are encouraged to monitor the long-term mobility
function of their patients on antihypertensive medication.
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